-
FDA warning on montelukast linked to prescription decline for asthma
Sami Hossri, MD, FCCP, said that while data show the warning prompted an immediate and sharp drop in new prescriptions, the shift in overall use was more modest.
Recent News
-
Riot medicine: Treating injuries from nonlethal force
At this CHEST 2026 session, a panel of experts will review the most common injury patterns seen in riot medicine and describe the most contemporary approach to their management.
-
Putting radon on your clinical radar
Hear from Clifford Mitchell, MD, MPH, Director of the Environmental Health Bureau at the Maryland Department of Health, about when to test, who is most at risk, and why clinicians should make radon awareness part of routine care.
-
Top reads from the CHEST journal portfolio – August 2026
Read new research from the journal portfolio on fine particulate matter as it relates to incident sleep apnea, respiratory muscle motor control in ventilator weaning, and measuring diagnostic yield in EBUS-TBNA using 19-gauge vs 21- or 22-gauge needles.
-
First-line zongertinib demonstrates durable responses in HER2-mutant NSCLC
Brett Bade, MD, and Katie Smith, MD, said the expansion of targeted therapies for lung cancer is an important advance, while noting that questions remain regarding the drug’s role in the first-line setting.
-
Exercise-induced desaturation common among patients with COPD during early inpatient PR
Michele Vitacca, MD, and Mara Paneroni, PhD, said data show a disconnect between oxygen desaturation and symptom measures, highlighting the importance of objective physiological monitoring.
-
TETON-1 treatment effects offer hope for patients with idiopathic pulmonary fibrosis
Christopher King, MD, FCCP, and Steven D. Nathan, MD, FCCP, discuss the clinical implications of inhaled treprostinil, including the medication’s potential use in future combination treatment strategies.
